Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Virnik, Konstantin ^a   Hockenbury, Max ^a   Ni, Yisheng ^a   Beren, Joel ^a,b   Pavlakis, George N ^c   Felber, Barbara K ^c   Berkower, Ira ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Center for Biologics   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Highly immunogenic; HIV MPER; Live viral vector; Long lasting; Memory B cells; Rhesus macaque; Rubella vaccine strain RA27 3; SIV Gag

Indexed keywords

DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; RUBELLA VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; MEMORY CELL; NONHUMAN; REPEATED DRUG DOSE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIABILITY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; RUBELLA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG CARRIERS; HIV; IMMUNOLOGIC MEMORY; MACACA MULATTA; RUBELLA VIRUS; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VACCINES, ATTENUATED;

EID: 84883753914     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-99     Document Type: Article

References (47)

1. Gallo RC. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 2005, 366:1894-1898. 10.1016/S0140-6736(05)67395-3, 16310557.
2. Saunders KO, Rudicell RS, Nabel GJ. The design and evaluation of HIV-1 vaccines. AIDS 2012, 26:1293-1302. 10.1097/QAD.0b013e32835474d2, 22706011.
3. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012, 12:396-407. 10.1016/j.chom.2012.09.008, 23084910.
4. Katz SL, Kempe CH, Black FL, Lepow ML, Krugman S, Haggerty RJ, Enders JF. Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. N Engl J Med 1960, 263:180-184. 10.1056/NEJM196007282630408, 14404830.
5. Hilleman MR, Buynak EB, Weibel RE, Stokes J. Live, attenuated rubella-virus vaccine. N Engl J Med 1968, 279:300-303. 10.1056/NEJM196808082790607, 4969117.
6. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998, 47:1-57.
7. Von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, Nappi F, Montefiori DC, Pavlakis GN, Marthas ML, Ruprecht RM, Felber BK. Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. J Virol 2002, 76:96-104. 10.1128/JVI.76.1.96-104.2002, 135725, 11739675.
8. Von Gegerfelt AS, Alicea C, Valentin A, Morrow M, Van Rompay KK, Ayash-Rashkovsky M, Markham P, Else JG, Marthas ML, Pavlakis GN, et al. Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res Hum Retroviruses 2006, 22:516-528. 10.1089/aid.2006.22.516, 16796527.
9. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941. 10.1126/science.1470917, 1470917.
10. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5:194-203. 10.1038/5557, 9930868.
11. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549. 10.1016/S0092-8674(01)00482-2, 11551502.
12. Johnston RE, Johnson PR, Connell MJ, Montefiori DC, West A, Collier ML, Cecil C, Swanstrom R, Frelinger JA, Davis NL. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23:4969-4979. 10.1016/j.vaccine.2005.05.034, 16005121.
13. Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 81:3414-3427. 10.1128/JVI.02453-06, 1866031, 17229693.
14. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527. 10.1038/nature10003, 3102768, 21562493.
15. Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18:546-556. 10.1016/j.copbio.2007.10.010, 2245896, 18063357.
16. Plotkin SA, Reef S. Rubella Vaccine. Vaccines 2013, 688-717. Philadelphia: Saunders, Plotkin SA, Orenstein WA, 6.
17. Spadaccini A, Virnik K, Ni Y, Prutzman K, Berkower I. Stable expression of a foreign protein by a replication-competent rubella viral vector. Vaccine 2010, 28:1181-1187. 10.1016/j.vaccine.2009.11.037, 19945412.
18. Virnik K, Ni Y, Berkower I. Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers. Vaccine 2012, 30:5453-5458. 10.1016/j.vaccine.2012.06.074, 3423898, 22776214.
19. Virnik K, Ni Y, Berkower I. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions. Vaccine 2013, 31:2119-2125. 10.1016/j.vaccine.2013.02.055, 23474312.
20. Pugachev KV, Galinski MS, Frey TK. Infectious cDNA clone of the RA27/3 vaccine strain of Rubella virus. Virology 2000, 273:189-197. 10.1006/viro.2000.0408, 10891421.
21. Frey TK. Molecular biology of rubella virus. Adv Virus Res 1994, 44:69-160.
22. Tzeng WP, Frey TK. Complementation of a deletion in the rubella virus p150 nonstructural protein by the viral capsid protein. J Virol 2003, 77:9502-9510. 10.1128/JVI.77.17.9502-9510.2003, 187411, 12915564.
23. Parkman PD, Phillips PE, Kirschstein RL, Meyer HM. Experimental rubella virus infection in the rhesus monkey. J Immunol 1965, 95:743-752.
24. Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, Weiker M, Weisgrau KL, Leon EJ, Rogers WE, Makowsky R, et al. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 2010, 84:9190-9199. 10.1128/JVI.00041-10, 2937616, 20592091.
25. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, Burton DR. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 2012, 109:18921-18925. 10.1073/pnas.1214785109, 3503218, 23100539.
26. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10:1651-1658. 10.1089/aid.1994.10.1651, 7888224.
27. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765. 10.1089/08892220152741450, 11788027.
28. Allen TM, Mothe BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, et al. CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol 2001, 75:738-749. 10.1128/JVI.75.2.738-749.2001, 113970, 11134287.
29. Loffredo JT, Sidney J, Wojewoda C, Dodds E, Reynolds MR, Napoe G, Mothe BR, O'Connor DH, Wilson NA, Watkins DI, Sette A. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol 2004, 173:5064-5076.
30. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, Patel V, Von Gegerfelt AS, Montefiori DC, Venzon DJ, et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci USA 2009, 106:15831-15836. 10.1073/pnas.0902628106, 2734879, 19717425.
31. Bosma TJ, Corbett KM, O'Shea S, Banatvala JE, Best JM. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995, 33:1075-1079. 228107, 7615708.
32. Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, et al. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 2009, 27:5120-5132. 10.1016/j.vaccine.2009.06.037, 19567243.
33. Tzeng WP, Frey TK. Functional replacement of a domain in the rubella virus p150 replicase protein by the virus capsid protein. J Virol 2009, 83:3549-3555. 10.1128/JVI.02411-08, 2663237, 19176617.
34. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999, 11:172-179. 10.1016/S0952-7915(99)80029-6, 10322151.
35. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 2009, 183:2708-2717. 10.4049/jimmunol.0901068, 3089979, 19625640.
36. Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, Daltabuit-Test M, Patterson LJ, Robert-Guroff M. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011, 29:3310-3319. 10.1016/j.vaccine.2011.02.066, 3079049, 21382487.
37. Bonaldo MC, Mello SM, Trindade GF, Rangel AA, Duarte AS, Oliveira PJ, Freire MS, Kubelka CF, Galler R. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virology journal 2007, 4:115. 10.1186/1743-422X-4-115, 2173888, 17971212.
38. Bonaldo MC, Martins MA, Rudersdorf R, Mudd PA, Sacha JB, Piaskowski SM, Costa Neves PC, de Santana MG V, Vojnov L, Capuano S, et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J Virol 2010, 84:3699-3706. 10.1128/JVI.02255-09, 2838090, 20089645.
39. Berzofsky J, Berkower IJ. Immunogenicity and Antigen Structure. Fundamental immunology 2008, 631-683. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, Paul WE, 6.
40. Montero M, Van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84. table of contents, 10.1128/MMBR.00020-07, 2268283, 18322034.
41. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010, 107:181-186. 10.1073/pnas.0912914107, 2806760, 20018688.
42. Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 2010, 84:5032-5042. 10.1128/JVI.00154-10, 2863839, 20219932.
43. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412. 10.1038/nature11544, 23151583.
44. Arthur LO, Bess JW, Sowder RC, Benveniste RE, Mann DL, Chermann JC, Henderson LE. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992, 258:1935-1938. 10.1126/science.1470916, 1470916.
45. Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V, Bergamaschi C, Chowdhury B, Zhang GM, Beach RK, et al. The p40 Subunit of Interleukin (IL)-12 promotes stabilization and export of the p35 subunit: Implications for improved IL-12 cytokine production. J Biol Chem 2013, 288:6763-6776. 10.1074/jbc.M112.436675, 3585113, 23297419.
46. McLean H, Redd S, Abernathy E, Icenogle J, Wallace G. Rubella. Centers for Disease Control and Prevention Manual for the surveillance of vaccine-preventable diseases 2012, Atlanta, GA: Centers for Disease Control and Prevention, HHS, Roush SW, McIntyre L, Baldy LM, 5.
47. Manikkavasagan G, Bukasa A, Brown KE, Cohen BJ, Ramsay ME. Oral fluid testing during 10 years of rubella elimination, England and Wales. Emerg Infect Dis 2010, 16:1532-1538. 10.3201/eid1610.100560, 3294398, 20875277.